Cresco Labs

Company Description

Cresco Labs Inc. is an integrated multi-state cannabis operator in the United States. The Company is licensed to cultivate, manufacture, and sell retail and medical cannabis products primarily through Sunnyside, Cresco Labs’ national dispensary brand, and third-party retail stores. Its family brands include Cresco, High Supply, Good News, Wonder Wellness Co., FloraCal Farms, Remedi and Mindy’s. Its portfolio consists of over 500 products. Its products are sold in over 1,400 dispensaries across the country. Cresco offers flower, liquid live resin vapes and concentrates available in a variety of product forms at dispensaries and retail locations. Its High Supply is lab-tested, and available in vape carts, vape pens, flowers, popcorn, shakes, shorties, and concentrates. Its Remedi products provide a consistent and trusted alternative to traditional pharmaceuticals like opioids. Mindy’s offers dosed edibles created by James Beard. It is the wholesaler of branded cannabis products.

Analysis

ANALYSIS: With an Obermatt 360° View of 1 (better than 1% compared with alternatives), overall professional sentiment and financial characteristics for the stock Cresco Labs are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with all four indicators below average for Cresco Labs. The consolidated Value Rank has a low rank of 20 which means that the share price of Cresco Labs is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 80% of alternative stocks in the same industry. The consolidated Growth Rank also has a low rank of 11, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is lower than for 11% of competitors in the same industry. The consolidated Safety Rank has a riskier rank of 20, which means that the company has a riskier financing structure than 80% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a low rank of 14, which means that professional investors are more pessimistic about the stock than for 86% of alternative investment opportunities. ...read more

Country

USA

Industry Pharmaceuticals

Size Small

Website crescolabs.com

Index

Sound Pay USA

Add to Watchlist

See Similar Stocks

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.